Our commitment to rheumatology

At UCB, patients are at the centre of everything we do. We, as a company, are committed to translating research and development into innovative solutions for patients living with rheumatoid diseases. With your support, we will continue to push scientific boundaries that will one day make a difference in the lives of all patients.

BIMZELX is indicated for the treatment of adult patients with:¹

• moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy
• active psoriatic arthritis. BIMZELX can be used alone or in combination with a conventional non-biologic disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate)
• active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy
• active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs)

Clinical use:

• Not authorized for use in pediatrics (<18 years of age)

Relevant warnings and precautions:

• Inflammatory bowel disease
• Serious hypersensitivity reactions
• Vaccinations
• Infections, including tuberculosis
• Pregnant or nursing women
• Women of childbearing potential

For more information:

Please consult the Product Monograph for important information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this piece. The Product Monograph is also available by calling 1-866-709-8444.